PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome

Sandra Lassalle, Sacha Nahon-Esteve, Eric Frouin, Camille Boulagnon-Rombi, Nicolas Josselin, Nathalie Cassoux, Raymond Barnhill, Boris Scheller, Stéphanie Baillif, Paul Hofman
2020 International Journal of Molecular Sciences  
Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8, PD-1 in CM and investigated whether there was an association between the expression of these markers and the BRAF and NRAS molecular profile as well as some clinico-pathological criteria. A total of
more » ... iteria. A total of sixty-five CM were assessed for PD-L1, PD-1, and CD8 expression by immunohistochemistry (IHC) and for BRAF and NRAS genomic alterations using molecular biology techniques and anti-BRAF and anti-NRAS antibodies. PD-L1 expression in tumour cells (TC) was very low or absent but detected in tumour-infiltrating immune cells (IC). A correlation was observed between the expression of PD-L1, CD8, and PD-1 in IC. No correlation between PD-L1 expression (in tumour and/or immune cells) and BRAF or NRAS mutations was observed. PD-L1 expression in IC correlated with a higher pTNM stage and PD-L1 expression in TC with worse disease-specific survival. PD-L1 expression is a potential prognostic biomarker that correlates with poor prognosis in CM patients.
doi:10.3390/ijms21239147 pmid:33266349 fatcat:sruvdtlq3ba6rb2ivg7ccemuwu